oral semaglutide nejm Semaglutide: the *ORAL* version also protects hearts - Semaglutide nejm2025 NEJM Oral Semaglutide NEJM: Examining Cardiovascular Outcomes and Efficacy

SOUL trialsemaglutideresults The landscape of metabolic medicine has been significantly reshaped by advancements in GLP-1 receptor agonists, and oral semaglutide stands at the forefront of this revolution. Research published in the prestigious NEJM (The New England Journal of Medicine) has critically examined the efficacy and safety of this medication, particularly its impact on cardiovascular outcomes and its utility in managing type 2 diabetes and obesity.

Understanding Oral Semaglutide's Role

Oral semaglutide has emerged as a pivotal treatment option, initially approved for the management of type 2 diabetes. However, its benefits extend beyond glycemic control作者：AM Lincoff·2023·被引用次数：2593—Whethersemaglutide can reduce cardiovascular riskassociated with overweight and obesity in the absence of diabetes is unknown. Methods: In a .... Studies, including those highlighted in NEJM, demonstrate that semaglutide also leads to significant weight loss, positioning it as a dual-action therapeutic. The oral formulation provides a convenient alternative to injectable forms, enhancing patient adherence and accessibility.

Cardiovascular Benefits: A Crucial Finding

A significant area of focus in NEJM research has been the assessment of oral semaglutide's impact on cardiovascular health. Landmark trials, such as the SOUL phase 3b trial, have provided compelling evidence. Findings from these studies indicate that oral semaglutide is associated with a significantly lower risk of major adverse cardiovascular events (MACE) compared to placeboShare your videos with friends, family, and the world.. For instance, one analysis revealed a hazard ratio of 0.作者：AS Brett·2025—Theoralversion lowered the incidence of adverse CV events by 2 percentage points during 4 years.86, signifying a notable reduction in cardiovascular risk2025年3月31日—... CKD, or both,oral semaglutide significantly reduced MACE compared to placebowithout increasing serious adverse events. SOUL published in NEJM .... This protective effect is particularly important for individuals with type 2 diabetes and coexisting atherosclerotic cardiovascular disease or other high-risk factors. The data suggests that oral semaglutide significantly reduced MACE in high-risk patients, including those with chronic kidney disease (CKD) or both, without increasing serious adverse events—a critical aspect highlighted in NEJM reporting.Oral Semaglutide Approved to Lower Cardiovascular Risk ... This reinforces the notion that semaglutide: the *ORAL* version also protects hearts.作者：S Wharton·2025·被引用次数：36—Oral semaglutideis approved for the treatment of type 2 diabetes(at doses up to 14 mg daily) and has been shown to lead to both weight loss ...

Efficacy Across Different Doses

Research has also delved into the efficacy of various doses of oral semaglutide. Studies have indicated that semaglutide was more effective at higher doses. For example, doses of oral semaglutide as high as 50 mg daily are safe and effective, according to some investigations. A dose of 25 mg once daily has shown a greater mean reduction in body weight compared to placebo in participants who are overweight or obese. Furthermore, semaglutide 25 mg and orforglipron are being evaluated and appear to outperform Rybelsus for obesity and diabetes management in emerging trialsWegovy Ingredients: What is in Wegovy?. The oral version of semaglutide is now approved for weight reduction, with a maintenance dose of 25 mg daily, demonstrating its expanded therapeutic role.

Comparison with Other Treatments

The emergence of oral semaglutide has also spurred comparisons with other metabolic treatmentsRetatrutide: The New Triple-Agonist Weight Loss Treatment. While Wegovy contains the active ingredient semaglutide, a GLP-1 receptor agonist, oral semaglutide offers a different delivery method.STRIDE and SOUL: Semaglutide Improves PAD Outcomes For individuals seeking weight management, options like prescription weight loss treatments Mounjaro, Wegovy, Orlistat, and Xenical are available. However, the data presented in NEJM on the cardiovascular benefits of oral semaglutide adds a crucial dimension to treatment decisions.

Future Directions and Ongoing Research

The scientific community continues to explore the full potential of semaglutide and related compounds.Low Dose Oral Semaglutide for Overweight Adults (OASIS-4) Research is ongoing to understand whether semaglutide can reduce cardiovascular risk associated with overweight and obesity even in the absence of diabetesCardiovascular outcomes with oral semaglutide in high-risk .... The development of newer agonists, such as retatrutide, a triple-agonist weight loss treatment, signifies the continuous innovation in this field.

In conclusion, the body of evidence, prominently featured in publications like NEJM, underscores the significant clinical value of oral semaglutide. Its proven ability to improve cardiovascular outcomes, manage type 2 diabetes, and facilitate weight loss makes it a cornerstone therapy in modern metabolic medicine. The ongoing research promises to further elucidate its multifaceted benefits and applications.Science News from ACC 2025 - Professional Heart Daily